In a study using MLL-rearranged AML cells, the HDAC inhibitor chidamide, a member of the benzamide class that has been approved by the Chinese FDA for treatment of relapsed or refractory peripheral T cell lymphoma (PTCL), showed synergistic effects with the MLL-menin interaction inhibitor MI-3 on cell growth and apoptosis. This evidence concerns the gene KMT2A and peripheral T-cell lymphoma, not otherwise specified.